This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We appreciate the comment by Palma on our research.1 The presence of serum AAV2 neutralizing antibodies (nAbs) was determined using a validated ELISA method at baseline and then at 1-, 3-, 6-, and 12-month postinfusion of AAV2-AADC gene therapy. At baseline, all treated participants met the inclusion criterion with nAb ≤1:1,200 and 11 participants (73%) had nAb below the lower limit of detection. Twelve months after administration of VY-AADC01, most participants (12, 80%) developed nAb at titers ranging from 1:57 to 1:7,273, whereas 2 participants from cohort 1 and 1 participant from cohort 2 had no detectable nAb. Peak titers appeared at 6 months with either stable or lower titers at 12 months. Neither the presence of preexisting nAb above the detection limit nor an increase in nAb titer from baseline precluded an increase in 6-[18F]fluoro-l-dopa uptake ratio after administration of VY-AADC01. These findings, along with the clinical stability of these participants over the 3-year study, suggest that an inflammatory response to AAV2 did not affect AADC gene expression.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
